摘要
目的分析早期糖尿病肾病患者应用百令胶囊与利拉鲁肽联合治疗的临床价值以及对其产生的影响。方法选取笔者所在医院2018年6月—2019年4月收治的98例早期糖尿病肾病患者,根据抽签法将其平均分成两组(试验组与参照组),一组纳入49例。参照组运用利拉鲁肽单一治疗,试验组运用百令胶囊与利拉鲁肽联合治疗。对其治疗前后三酰甘油、血尿素氮、总胆固醇、糖化血红蛋白、空腹血糖以及临床不良反应发生率进行统计分析。结果治疗前两组对比均差异无统计学意义(P>0.05),治疗后试验组三酰甘油、血尿素氮、总胆固醇等指标均低于参照组同等指标,差异有统计学意义(P<0.05);治疗前两组患者空腹血糖与糖化血红蛋白对比差异无统计学意义(P>0.05),治疗后试验组空腹血糖与糖化血红蛋白均低于参照组同等指标,差异有统计学意义(P<0.05);试验组不良反应总发生率4.08%(2/49)低于参照组不良反应总发生率18.37%(9/49),差异有统计学意义(P<0.05)。结论治疗早期糖尿病肾病选取百令胶囊与利拉鲁肽联合治疗,可全面改善患者临床各项指标水平,临床不良反应发生率较低,用药安全系数较高。
Objective To analyze the clinical value and influence of Bailing capsule combined with liraglutide in patients with early diabetic nephropathy. Methods A total of 98 patients with early diabetic nephropathy admitted to the author’s hospital from June 2018 to April 2019 were selected and divided into 2 groups(test group and reference group) according to the lottery method, and one group included 49 cases. The reference group was treated with liraglutide alone, and the experimental group was treated with Bailing capsules and liraglutide in combination. The incidence of triacylglycerol, blood urea nitrogen, total cholesterol, glycosylated hemoglobin, fasting blood glucose and clinical adverse reactions before and after treatment were statistically analyzed. Results There was no statistically significant difference between the two groups before treatment(P>0.05). After treatment, the indicators of triacylglycerol, blood urea nitrogen, and total cholesterol in the test group were lower than the same indicators in the reference group, the difference was statistically significant(P<0.05);Before treatment, there was no statistically significant difference in fasting blood glucose and glycosylated hemoglobin between the two groups of patients(P>0.05). After treatment, the fasting blood glucose and glycosylated hemoglobin of the test group were lower than the same indicators in the reference group, the difference was statistical significance(P<0.05);the test group with the total incidence rate of 4.08%(2/49) cases was lower than the total incidence rate of 18.37%(9/49)cases in the reference group, the difference was statistically significant(P<0.05). Conclusion The combination therapy of Bailing capsule and liraglutide for the treatment of early diabetic nephropathy can comprehensively improve the level of various clinical indicators in patients, with a lower incidence of clinical adverse reactions and a higher drug safety factor.
作者
葛洪燕
GE Hong-yan(Department of Endocrinology,Luzhong Hospital of Peking University,Zibo,Shandong Province,255400 China)
出处
《糖尿病新世界》
2020年第18期156-157,160,共3页
Diabetes New World Magazine
关键词
糖尿病
肾病
治疗效果
百令胶囊
联合治疗
利拉鲁肽
Diabetes
Nephropathy
Therapeutic effect
Bailing capsule
Combination therapy
Liraglutide
